doxorubicin-tumor homing peptide conjugate (ILEX)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Namedoxorubicin-tumor homing peptide conjugate (ILEX)
Drug Alias NameTHP-dox
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionTopoisomerase II inhibitorsDNA intercalatorsVirus DNA polymerase inhibitors
TargetsVirus DNA polymeraseTopoisomerase IIDNA
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSanford-Burnham Medical Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesILEX Oncology IncSanford-Burnham Medical Research Institute
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A